December 10, 2021 Bio/Pharma/CRO Product Launch

New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free survival improvement for the combination compared with Tecentriq alone CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell... Read more

December 7, 2021 Microscopy

Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19

EMA’s CHMP recommended the approval yesterday Approval based on results from four phase III studies in over 5,500 patients Actemra/RoActemra has also been provisionally approved in Australia for the treatment of COVID-19 Basel, 07 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for... Read more

December 6, 2021 Uncategorized

Roche completed the repurchase of Roche shares from Novartis

Basel, 6 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November 2021, Roche and Novartis had announced this repurchase. The Extraordinary General Meeting of Roche Holding Ltd passed the resolutions required for the repurchase and the... Read more

December 6, 2021 Uncategorized

Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections

The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions Affordable and small, instrument-free testing kit enables convenient use for healthcare professionals at different point of care locations and in resource-limited settings... Read more

December 3, 2021 PAI Top-10

Changes in the Board of Directors

03 December 2021 Basel, 3 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting (AGM) scheduled for 15 March 2022. Mr Paul Bulcke, who has been serving on the Board of... Read more

December 3, 2021 PAI Top-10

Changes in the Board of Directors

Basel, 3 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting (AGM) scheduled for 15 March 2022. Mr Paul Bulcke, who has been serving on the Board of Directors since 2011,... Read more

December 3, 2021 Liq. Handling & Robotics

Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant

Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions Three new testing kits are among the first to specify the mutations of the recently discovered Omicron variant, and can help manage the evolving COVID-19 pandemic Use of... Read more

December 1, 2021 Life Science Tools M&A, Partnerships Product Launch

Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche’s LightCycler PCR instruments TIB Molbiol will continue to focus on the research and development... Read more

November 26, 2021 Uncategorized

Roche Extraordinary General Meeting 2021

All proposals of the Board of Directors approved Audited statutory interim financial statements (standalone financial statements) of the Company as of 31 October 2021 approved Share capital reduction by cancellation of 53,309,000 bearer shares with a nominal value of CHF 1 each approved Basel, 26 November 2021 – On 4 November 2021, Roche (SIX: RO,... Read more